Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 11.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,918 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the period. Pacer Advisors Inc.’s holdings in Arrowhead Pharmaceuticals were worth $525,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ARWR. HighTower Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 11.5% in the 3rd quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company’s stock worth $2,401,000 after buying an additional 12,706 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $659,000. Erste Asset Management GmbH acquired a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at approximately $924,000. Geode Capital Management LLC increased its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after purchasing an additional 26,171 shares in the last quarter. Finally, International Assets Investment Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $14,420,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 32,729 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the transaction, the insider now owns 272,122 shares in the company, valued at approximately $5,393,458.04. The trade was a 10.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Christopher Richard Anzalone sold 11,520 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $19.05, for a total transaction of $219,456.00. Following the sale, the chief executive officer now directly owns 3,764,252 shares of the company’s stock, valued at approximately $71,709,000.60. This trade represents a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 147,432 shares of company stock worth $2,957,986. 4.30% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Stock Up 5.0 %

Shares of ARWR opened at $19.68 on Wednesday. The firm has a market cap of $2.46 billion, a PE ratio of -3.92 and a beta of 0.95. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The company’s fifty day moving average is $20.85 and its two-hundred day moving average is $21.56. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $17.05 and a fifty-two week high of $36.72.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ARWR. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday, November 27th. HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, January 23rd. Sanford C. Bernstein reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a report on Friday, November 29th. Citigroup lowered their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. Finally, Chardan Capital reissued a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $43.33.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.